1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Therapeutic Vaccines Market 2014-2018

Global Therapeutic Vaccines Market 2014-2018

  • March 2014
  • -
  • Infiniti Research Limited
  • -
  • 54 pages

About Therapeutic Vaccines

A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period.
TechNavio's analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market.
TechNavio's report, the Global Therapeutic Vaccines Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions
• Americas

Key Vendors
• Agenus Inc.
• Bavarian Nordic A/S.
• Dendreon Corp.
• GlaxoSmithKline plc
• Novartis International AG

Other Prominent Vendors
• Argos Therapeutics Inc.
• Celldex Therapeutics Inc.
• CEL-SCI Corp.
• Cytos Biotechnology AG
• GlobeImmune Inc.
• NewLink Genetics Corp.
• NovaRx Corp.
• Oncothyreon Inc.
• TVAX Biomedical Inc.
• TapImmune Inc.
• Vical Inc.
• Vaccinogen Inc.

Market Driver
• Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders
• Ongoing Development of a Large Number of Therapeutic Vaccines

Market Challenge
• Stringent Regulations
• Adverse Side Effects of Therapeutic Vaccines

Market Trend
• Improved Understanding of Immunology and Immunotherapy
• Increase in Mergers and Acquisitions

Key Questions Answered in this Report

• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

Table Of Contents

Global Therapeutic Vaccines Market 2014-2018
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Geographical Segmentation
08. Key Leading Countries
08.1 USA
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Pipeline Analysis
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Agenus Inc.
18.1.1 Business Overview
18.1.2 Key Information
18.1.3 SWOT Analysis
18.2 Bavarian Nordic A/S
18.2.1 Business Overview
18.2.2 Business Segmentation
18.2.3 Key Information
18.2.4 SWOT Analysis
18.3 Dendreon Corp.
18.3.1 Business Overview
18.3.2 Key Information
18.3.3 SWOT Analysis
18.4 GlaxoSmithKline plc
18.4.1 Business Overview
18.4.2 Business Segmentation
18.4.3 Key Information
18.4.4 SWOT Analysis
18.5 Novartis International AG
18.5.1 Business Overview
18.5.2 Business Segmentation
18.5.3 Key Information
18.5.4 SWOT AnalysisOther Reports in the Series

List of Exhibits

Exhibit 1: Market Research Methodology
Exhibit 2: Global Therapeutic Vaccines Market 2013-2018 (US$ billion)
Exhibit 3: Global Therapeutic Vaccines Market by Geographical Segmentation 2013
Exhibit 4: Segmentation of Therapeutic Vaccines under Clinical Trial, by Disease 2013
Exhibit 5: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Cancer 2013
Exhibit 6: Segmentation of Therapeutic Vaccines under Clinical Trial by Type of Tropical Infectious Disease 2013
Exhibit 7: Segmentation of Therapeutic Vaccines under Clinical Trial, By Physiological Disorders 2013
Exhibit 8: Late Stage Pipeline Analysis of Therapeutic Vaccines 2013
Exhibit 9: Business Segmentation of Bavarian Nordic A/S
Exhibit 10: Business Segmentation of GlaxoSmithKline plc
Exhibit 11: Business Segmentation of Novartis International AG

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Hepatitis C: KOL Insight

Hepatitis C: KOL Insight

  • $ 8 085
  • Industry report
  • September 2016
  • by Firstword Pharma

As hepatitis C cures multiply, how do experts evaluate the options? Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus ...

Chronic Lymphocytic Leukaemia: KOL Insight

Chronic Lymphocytic Leukaemia: KOL Insight

  • $ 8 085
  • Industry report
  • August 2016
  • by Firstword Pharma

How will established and emerging agents reshape the CLL treatment landscape? How do key opinion leaders (KOLs) see the future treatment paradigm for chronic lymphocytic leukaemia (CLL) shaping up? Will ...

Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Therapy Market in Denmark

  • October 2016
    11 pages
  • Therapy  


  • Denmark  

View report >

Opioid Market in the US

  • October 2016
    32 pages
  • Opioid  


    Infectious Dise...  

  • United States  



View report >


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.